Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation

第1相前期 完了 NCT04130061

概要

This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.

Number of Participants With Adverse Events

1 month · Participants

Number of Participants With Post Op Atrial Fibrillation Between Patients Who Receive hAM and Controls

1 month · Participants

proBNP (Serum) Between Groups at Time of Surgery

Surgery · pg/mL

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
• Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
• Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation — Massachusetts General Hospital
• Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.

すべての治験